Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: Potential candidates for the control of neurodegenerative diseases

Journal of Neural Transmission, Supplement

Volumn , Issue 71, 2006, Pages 163-172

  Zheng, H ^a   Blat, D ^a   Fridkin, M ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

'M 99'; ASPARAGINYLALANYLPROLYLVALYLSERYLISOLEUCYLPROLYLGLUTAMINE; COPPER; DEFEROXAMINE MESYLATE; IRON; M 98; METAL; METAL CHELATE; OXIDOPAMINE; UNCLASSIFIED DRUG; ZINC; ADRENERGIC RECEPTOR STIMULATING AGENT; DEFEROXAMINE; NAPVSIPQ PEPTIDE; NEUROPROTECTIVE AGENT; OLIGOPEPTIDE; SIDEROPHORE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALZHEIMER DISEASE; ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN HOMOGENATE; CANCER CELL CULTURE; CHELATION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE CONTROL; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; HEAVY METAL POISONING; HUMAN; HUMAN CELL; LIPID PEROXIDATION; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ANIMAL; BRAIN; CELL LINE; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; IN VITRO STUDY; METABOLISM;

ADRENERGIC AGENTS; ANIMALS; BRAIN; CELL LINE; CELL SURVIVAL; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; METALS; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; OXIDATIVE STRESS; OXIDOPAMINE; RATS; SIDEROPHORES; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 34248586304     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-33328-0_18     Document Type: Article

References (55)

1. Anderegg G, L'Eplattenier F, Schwarzenbach G (1963) Hydroxamate complexes: Application of the pH method. Helvetica Chimica Acta 46: 1400-1408
2. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI (1998) Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273: 12817-12826
3. Ben-Shachar D, Nava Kahana N, Kampel V, Warshawsky A, Youdim MHB (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxy-dopamine lession in rats. Neuropharmacol 46: 254-263
4. Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, Golian T, Gozes I (2004) Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Expl Therapeutics 309: 1190-1197
5. Bush AI, Pettingell WH, Multhaup G, Paradis MD, Vonsattel J-P, Beyreuther K, Masters CL, Tanzi RE (1994) Rapid induction of Alzheimer A b amyloid formation by zinc. Science 265: 1464-1467
6. Carter P (1971) Spectrophotometric determination of serum iron at the submicrogram level with a new reagent (ferrozine). Anal biochem 40: 450-458
7. Casetta I, Govoni V, Granieri E (2005) Oxidative stress, antioxidants and neurodegenerative diseases. Current Pharmaceutical Design 11: 2033-2052
8. Clements A, Allsop D, Walsh DM, Williams CH (1996) Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease. J Neurochem 66: 740-747
9. Desport JC, Couratier P (2002) Oxidative stress in neurodegenerative diseases. Nutr Clin Metab 16: 253-259
10. Drakarch B, van Muiswinkel FL (2000) Drug treatment of Parkinson's disease. Time for phase II. Biochem Pharmacol 59: 1023-1031
11. Gal S, Zheng H, Fridkin M, Youdim MBH (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: In vivo selective brain monoamine oxidase inhibition and neuro-protective activity. J Neurochem 95: 79-88
12. Gilgun-Sherki Y, Melamed E, Offen D (2001) Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood-brain barrier. Neuropharmacol the blood-brain barrier. Neuropharmacol 40: 959-975
13. Glinka Y, Gassen M, Youdim MBH (1997) Mechanism of 6-hydroxydopamine neurotoxicity. Adv Res Neurodegen 5: 55-66
14. Gozes I, Lilling G, Glazer R, Ticher A, Ashkenazi IE, Davidson A, Rubinraut S, Fridkin M, Brenneman DE (1995) Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J Pharmacol Exp Ther 273: 161-167
15. Gozes I, Bardea A, Bechar M, Pearl O, Reshef A, Zamostiano R, Davidson A, Rubinraut S, Giladi E, Fridkin M, Brenneman DE (1997) Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease. Ann NY Acad Sci 814: 161-166
16. Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD (2003) From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: A view of neuroprotection and cell division. J Mol Neurosci 20: 315-322
17. Gozes I, Steingart RA, Spier AD (2004) NAP mechanisms of neuroprotection. J Mol Neurosci 24: 67-72
18. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P, Youdim MBH (2004) Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111: 1543-1573
19. Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59: 1609-1623
20. Harris DC, Aisen P (1973) Facilitation of Fe(II) autoxidation by Fe(III) complexing agents. Biochimica et biophysica acta 329: 156-158
21. Huang X, Cuajungco MP, Atwood CS, Moir RD, Tanzi RE, Bush AI (2000) Alzheimer's disease, b-amyloid protein and zinc. J Nutr 130: 1488S-1492S
22. Jellinger KA (1999) The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14: 115-140
23. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37: 899-909
24. Kayyali R, Pannala AS, Khodr H, Hider RC (1998) Comparative radical scavenging ability of bidentate iron(III) chelators. Biochem Pharmacol 55: 1327-1332
25. Lan J, Jiang DH (1997) Desferrioxamine and Vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 104: 469-481
26. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, Youdim MBH (2003) Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drags 17: 729-762
27. Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52
28. Mattson MP (2004) Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann NY Acad Sci 1012: 37-50
29. Maynard CJ, Bush AI, Masters CL, Cappaiand R, Li QX (2005) Metals and amyloid-β in Alzheimer's disease. Int J Exp Path 86: 147-159
30. McDowell I (2001) Alzheimer's disease: insights from epidemiology. Aging 13: 143-162
31. Miura T, Suzuki K, Kohata N, Takeuchi H (2000) Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. Biochemistry 39: 7024-7031
32. Moreira PI, Siedlak SL, Aliev G, Zhu X, Cash AD, Smith MA, Perry G (2005) Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J Neural Transm 112: 921-932
33. Munoz-Patino AM, Labandeira-Garcia JL (2000) Autoxidation and neurotoxicity of 6-hydroxy-dopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem 74: 1605-1612
34. Obrien PJ (1969) Intracellular mechaniims for the decomposition of a lipid peroxide: decomposition of a lipid peroxide by metal ions, nerve compounds, and nucleophiles. Can J Biochem 47: 485-492
35. Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I (2000) Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res 854: 257-262
36. Pipette LH, Baxely LH, Graver TA, Harwood PJ (1983) A Comparative Kinetic Study of the Initiation of Lipid Peroxidation with OH Radicals and Ferrous Ion. In: Bors W, Saran M, Tait D (eds) Oxygen Radicals in Chemistry and Biology. Walter de Gruyter & Co., Berlin, p 137
37. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21: 4183-4187
38. Pratico D, Sung S (2004) Lipid peroxidation and oxidative imbalance: Early functional events in Alzheimer's disease. J Alzheimer's Disease 6: 171-175
39. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520
40. Sachs C, Jonsson G (1975) Mechanism of action of 6-hydroxydopamine. Brain Res 99: 277-291
41. Seitz G, Stegmann HB, Jager HH, Schlide HM, Wolburg H, Roginsky VA, Niethammer D, Bruchelt G, Shoham S, Youdim MBH (2000) Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell Mol Biol 46: 743-760
42. Sen CK (1998) Redox signaling and the emerging therapeutic potential of thiol antioxidants. Biochem Pharmacol 55: 1747-1758
43. Singh S, Khodr H, Taylor MI, Hider RC (1996) Therapeutic iron chelators and their potential side effects. Biochem Soc Symp 61: 127-137
44. Soto C (1999) Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol Med Today 5: 343-350
45. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Turnquist TD, Sandell EB (1968) Stability constants of iron(III)-8-hydroxylquinolinecomplexes. Anal Chim Acta 42: 239-245
46. Takanashi M, Mochizuki H, Yokomizo K, Hattori N, Mori H, Yamamura Y, Mizuno Y (2001) Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP). Parkinson's Relat Disord 7: 311-314
47. Walkinshaw G, Waters CM (1994) Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis. Neurosci 63: 975-987
48. Wilkemeyer MF, Chen S, Menkari CE, Brenneman DE, Sulik KK, Charness ME (2003) Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity. Proc Nati Acad Sci USA 100: 8543-8548
49. Youdim MBH, Buccafusco JJ (2005a) CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases. J Neural Transm 112: 519-537
50. Youdim MBH, Buccafusco JJ (2005b) Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26: 27-35
51. Zecca L, Youdim MBH, Riedrere P, Connor JR, Crichton RR (2004) Iron, brain, ageing and neurodegenerative disorders. Nat Rev Neurosci 5: 863-873
52. Zheng H, Youdim MBH, Weiner LM, Fridkin M (2005a) Novel potential neuroprotective agent with both iron chelating and amino acid-based derivatives targeting the central nervous system neurons. Biochem Pharmacol 70: 1642-1652
53. Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MBH (2005b) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95: 68-78
54. Zheng H, Weiner LM, Bar-Am O, Epsztejn M, Cabantchik I, Warshawsky A, Youdim MBH, Fridkin M (2005c) Design, synthesis and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in neurodegenerative diseases. Bioorg Med Chem 13: 773-783
55. Zheng H, Youdim MBH, Weiner LM, Fridkin M (2005d) Synthesis and Evaluation of Peptidic Metal Chelators for Neuroprotection in Neurodegenerative Diseases. J Pept Res 66: 190-203